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cers (SCLC) showed telomerase activity,
while telomerase activity varied in non-small
cell lung cancers (NSCLC).
Normally, telomerase is inactive in somat-
ic cells, which die naturally after a number of
cell divisions. Each time a chromosome is
reproduced, the telomere, a small part at the
end of the chromosome, is lost. In order to
counter these losses, each of the chromo-
some's telomeres carries repeating nucleotide
sequences. However, once those sequences are
used up, the cell stops dividing and dies. Cells
that need to continue to reproduce, such as
germ line reproductive cells, carry telomerase,
a DNA polymerase which adds repeating
nucleotide sequences to the shortened telom-
eres. Previous studies have also found telom-
erase activity in malignant
tumors of numerous cell types
including breast, prostate,
colon, skin, and brain, suggest-
ing that the enzyme allows can-
cercells to continue todivide.
The reactivation of telom-
erase may occur at either of
two stages of cell death, mor-
tality stage 1 (MI) or mortali-
ty stage 2 (M2). During MI,
cells lose their ability to divide,
a state known as senescence.
The malfunction of a tumor-
suppressor gene or the muta-
tion of an oncogene might
transform a cell, allowing it to
avoid senescence. However,
although such defects extend
the cell's life span, it will even-
tually die. During M2, cells
reach a point known as crisis,
in which most cells die; how-
ever, the survivors are immortal and capable
ofunlimited proliferation.
The presence ofNSCLC tumors contain-
ing both mortal and immortal cells suggests
that the immortalization ofan existing tumor
cell is rare, requiring two separate events and
occurring after manycell divisions. In SCLCs,
cells show signs ofhaving already undergone
the number of divisions and chromosomal
changes necessary for the reactivation of
telomerase before becoming cancerous.
Shay and his colleagues observed varia-
tions in telomerase activity that may reflect
characteristics ofthe cells or the ratio ofmor-
tal to immortal cells within the tumors.
However, although levels oftelomerase activi-
ty varied dramatically among some of the
samples tested, immortalized lung cancer cell
lines all showed similar activity, whether
SCLC or NSCLC. The study's authors cau-
tiously suggest that once a lung cell is immor-
talized, it achieves a set level of telomerase
activity no matterwhat its type.
The absence oftelomerase activity in some
tumors may indicate that they consist entirely
ofmortal cells. A previous study, published in
Science, found that benign fibroid tumors did
not have telomerase activity. According to
Shay's study, "Ifcancers that have mortal cells
exist, their growth might be self-limiting in
contrastto thosethatconsistofimmortal cells,"
apossible reasonwhySCLCsarethemostdiffi-
cult lung cancers to treat. This distinction
between cellpopulations withtelomerase activi-
ty and those without it may serve as the basis
fortests to predict thecells' capacityfor contin-
ued proliferation and, therefore, the disease's
severity. Telomerase activity might even be
found in cells obtained from a patient's lung
wash, a procedure Shay used in his study and
one which is already commonly used for other
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Solid gold silos? Two containers atthe Fernald nuclear plant, slated for clean-
up, hold medically priceless amounts of radium.
typesoflungcancerdiagnostic tests.
Researchers are already searching for a
drug that inhibits telomerase, in hopes ofcut-
ting short the lives of the most proliferative
lung cancer cells. In the August 31 issue of
Science, researcher Calvin B. Harley ofGeron
Corporation andhis colleagues at ColdSpring
Harbor Laboratory reported that they were
able to produce reverse RNA that blocked the
action oftelomeraseandcaused HeLacells, an
experimental cancer cell line, to begin dying
after 23-26 cell divisions. While Harley
emphasizes that a drug able to mimic this
effectmaytakeyears to findanddevelop, such
a drug could prevent the spread of cancer
without harming normal cells. In an interview
with the Associated Press, Shay said, "This is
the first laboratory proof that inhibiting of
telomerase RNA will result in limiting cell
division.... This is the most important next
step in telomerase research."
In an earlier AP interview Shay pointed
out that the existence of metastatic tumors
lacking telomerase activity implies that there
are other immortalization mechanisms.
According to molecular epidemiologist Curtis
Harris of the National Cancer Institute, a
mechanism that enabled cells to escape senes-
cence would be one that bypasses the problem
ofshrinking telomeres, such as DNArecombi-
nation, probably avery inefficient mechanism.
Ifdrugs were developed to target telomerase,
these alternate mechanisms ofimmortalization
might come into play to allow tumor cells to
escape senescence, says Harris. Even in those
cells where telomerase inhibitors successfully
prevented immortalization, any remaining
supply of telomeric repeats would allow the
cell to continue to divide for a finite period of
time, with possible adverse consequences to
the patient. In addition, other cells in the
body, such as stem cells and stomach
cells, might be sensitive to telomerase
inhibitors, leading to serious side
effects.
What a Waste
It may seem unusual for U.S. scien-
tists and medical researchers to lobby
strongly against a government pro-
gram to clean up the contaminated
Fernald nuclear plant in Ohio, but
that's exactly what's happening. The
Fernald plant, which processed ura-
nium for nuclear weapons from
1951 to 1989, now has about
10,000 tons of radioactive waste
contained in two special silos.
Within this waste, however, is a
medically priceless stockpile of radi-
um as well as millions of dollars
worth of gold and other precious
metals. Scientists are arguing that
this radium, which is scheduled to be dis-
posed ofstarting in early 1996, may be criti-
cal to saving the lives ofcancer patients ifa
clinical trial that attempts to cure cancer with
a radium-based monoclonal antibody is suc-
cessful.
David Scheinberg, a medical oncologist
at the Memorial Sloan Kettering Cancer
Center, is enrolling patients in a clinical trial
to test a new methodology that links a radi-
um-based isotope, bismuth-213, to a mono-
clonal antibody to target cancer cells. The
treatment is being tested on 10-20 patients
who have acute myeloid leukemia (AML) or
chronic myeloid leukemia (CML). In a pre-
liminary experiment using a leukemia mouse
model, the bismuth-213 antibody treatment
led to remission of the diseases and longer
survival rates. If the phase I trial scheduled
for November is successful, it will be fol-
lowed by a slightly larger study within a year
ofthe phase I results. Iffurther clinical trials
show positive results and the treatment is
approved by the FDA, it could potentially be
992 Volume 103, Number 11, November 1995 * Environmental Health PerspectivesForum
used to treat approximately 30,000 people in
the United States who have CML andAML.
Experiments are also underway to test this
isotope therapy in other types ofcancers.
Radium is a very rare element. The
stockpile of radium-containing waste at the
Fernald plant is the largest cache in the
world. The 4,500 grams ofradium present at
the site could provide thousands ofdoses of
the new cancer treatment and has been esti-
mated to be worth about $68 million. The
cost of extracting the radium has not been
estimated, and it has not been determined
whowould payfor it.
The waste has been scheduled to be
melted into a glasslike substance through a
process called vitrification in a joint cleanup
effort by the Department ofEnergy and the
EPA. The DOE has contracted with the
Fernald Environmental Restoration
Management Company (FERMCO) to
manage the cleanup. "A pilot vitrification
run is scheduled to begin in November" said
Perry Richardson, spokesperson for FERM-
CO. "Depending on the pilot run, a full-
scale cleanup could begin in mid-1996 and
maylast two to threeyears."
Both the DOE and FERMCO oppose
delaying the cleanup to remove the radium.
Mike Jacobs, a public affairs officer at the
DOE in Cincinnati, explains one reason
why: "The DOE gets a certain budget for
each site per year. If the radium extraction
process is costly, it may deplete a majority of
the cleanup funds." Jacobs asserts that the
DOE "is open to any suggestions from the
medical community" but says they have not
received any formal requests to temporarily
halt the cleanup to extract the radium.
The residents of the towns surrounding
the Fernald plant are excited that the cleanup
is about to begin. "They, along with the
DOE, EPA, and other groups, have wanted
the site cleaned up for years," said Jacobs.
Although residents understand the potential
good that the waste can contribute, they
wonder why this issue did not surface earlier.
Residents also have many questions regard-
ing the logistics and the implications ofradi-
um extraction, few ofwhich can be answered
satisfactorily, as no group has prepared an
extraction plan.
Manoranjan Misra, a professor ofchemi-
cal engineering at the University of Nevada,
Reno, is an expert in separation processes. He
estimates that radium extraction at Fernald
may cost $5 to $6 million, not including
additional costs to refine and purify the radi-
um to be used as a medical therapy. Misra
explained a possible radium recovery process
which uses physical separation and other
techniques: "Special chemicals are added to
the vastwaste pile to dissolve barium and ura-
nium and float them to the top. This top
layer will contain most of the radium
[attached to the barium] and will weigh in at
about five to ten tons. It can be removed and
subsequently processed into pure radium
without slowing the waste cleanup." The
DOE and FERMCO want the scientists to
extract the radium from thevitrified material,
although, according to Misra, there is no
known process fordoingthis.
All parties involved in the Fernald
cleanup have stated they would like to save
the radium ifit is economically and logistical-
ly possible. IfScheinberg and other scientists
obtain positive clinical trial results with med-
ical isotopes, the loss ofthe Fernald radium to
thecleanup process will reallybe awaste.
AT Gene Isolated
A gene that when mutated causes a rare and
fatal hereditary disorder has been isolated by
a team ledbyYosefShiloh, ageneticist at Tel
Aviv University in Israel. "This is a turning
point in our understanding ofAT [ataxia
telangiecstasia], but also in our understand-
ing ofcell growth and cancer," said Shiloh at
a news conference announcing the discovery
of the gene. The research suggests that the
gene may also be a major contributor to
hereditary forms ofbreast cancer.
Researchers hope the gene will aid in
decipheringhowcellswork, aswell as provide
new understanding of how cancers develop.
"It's a biologically complex area [that we
have] very little way ofunraveling. By having
the gene, we've broken the logjam," said
Richard Gatti, a member of the team at the
University ofCalifornia at LosAngeles. "This
is a Rosettastone gene," he said.
Scientists believe the gene encodes a pro-
tein that recognizes DNA damage and halts
cell growth and division until the damage is
repaired. In patients with AT, damaged cells
continue to replicate and divide without
being repaired. "The molecule transmits the
message [to halt cell division] to the cell, and
somewhere the telephone lines were down,"
said Gatti.
The gene was located as the result of a
hunt by four laboratories-Shiloh's, Gatti's,
one led by Malcolm Taylor at the University
of Birmingham, U.K., and one led by Pat
Concannon at the Virginia Mason Research
Center in Seattle, Washington-using posi-
tional cloning. "First we do linkage analysis,
and then go in and pluck out the gene. It is
done purely mathematically," Gatti said.
AT affects children, who inherit two
defective copies of this gene (one from each
parent), at an early age, causing the deterio-
ration ofmuscle coordination and defects in
the immune system. AT also causes extreme
sensitivity to radiation, sometimes to the
point offatality. Patients with AT frequently
develop cancers, usually leukemia and lym-
phomas, and most patients succumb to the
disease by their 20s due to infection or can-
cer. The disease affects about 1 in every
40,000 people worldwide. About 500
American children have AT, and an estimat-
ed 2.5 million Americans are carriers ofone
copyoftheAT mutation.
Researchers are now studying the possi-
bility that carriers have increased risks ofcan-
cer. It has been estimated that carriers are
four times more likely to develop cancer and
that female carriers have a fivefold increased
riskofdeveloping breast cancer.
A possibility is that the very procedures
used to detect breast cancer in women may
be increasing the risk ofdeveloping cancer in
female carriers because ofits link to radiation
sensitivity. In 1991, Michael Swift of New
York Medical College in Valhalla proposed
that diagnostic X-rays might cause breast
cancer in certain women. He showed that
women from AT families who have breast
cancerwere more likely to have been exposed
to high-dose diagnostic or therapeutic X-rays
than family members without breast cancer.
This finding was consistent with data indi-
cating that cultured cells containing the
mutated gene suffer more DNA damage and
have a higher death rate than do normal cells
when exposed toX-rays.
Swift's theory is controversial because the
amounts of radiation used in current diag-
nostic X-rays are lower than an individual's
normal annual exposure to natural radiation
and lower than the doses given to the cul-
tured cells. Now that the gene has been
cloned, theories such as Swift's can be tested.
The National Center for Human Genome
Research, the National Cancer Institute, and
the Danish Cancer Registry in Copenhagen
are initiatingstudies to research this possibili-
ty. Meanwhile, the NCI has said that women
should continue to follow the recommended
mammography screening for breast cancer.
"We hope to find [the gene's] role in radia-
tion sensitivity, so that we can find out how
to protect and who to protect," said Gatti.
"We can now do the experiments that with-
out the genewe had no handle on."
Richard Paules, head of the Growth
Control and Cancer Group in the Labor-
atory of Environmental Carcinogenesis and
Mutagenesis at the NIEHS says, "a better
understanding of this important pathway
contolling cell proliferation holds the
promise ofdeveloping new diagnostic proce-
dures and offers hope that scientists may be
able to design better therapies for cancers."
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